The CRISPR Revolution and the Power We Are Not Ready For

Are we outsourcing our future?

CRISPR is usually introduced with some version of the same promise: we may finally be able to fix disease at its source.

That promise is real. So is the reason I find the technology impossible to stop thinking about.

CRISPR gives scientists the ability to target specific sections of DNA and make changes that would have been unimaginable not very long ago. This is no longer something waiting for the distant future. CRISPR-based treatments have already moved into approved medicine, including therapies for sickle cell disease and transfusion-dependent beta thalassemia.

That is extraordinary. It also means some of the questions science fiction has been asking for decades are beginning to lose the fiction part.

What CRISPR Changes

The simplest explanation of CRISPR is that it gives scientists a way to find a particular genetic sequence and alter it. The actual biology is considerably more complicated, and the process is not infallible. Researchers still have to contend with unintended edits, delivery challenges, long-term effects, and the fact that changing cells in a laboratory is very different from safely treating a human being. The FDA continues to identify off-target editing as one of the risks associated with CRISPR-based treatment.

Still, consider what the capability means. For most of human history, an inherited genetic disorder was something medicine could treat, manage, or sometimes work around. Increasingly, researchers can contemplate intervening much closer to the source of the problem itself.

Once we can alter biology intentionally, the difficult questions don't stay inside the laboratory. They move into hospitals, insurance systems, regulatory agencies, legislatures, courtrooms, and eventually families sitting across from doctors trying to decide what they are willing to risk.

Who gets access? What counts as treatment? How much uncertainty is acceptable when the alternative is a devastating disease? What happens as the line between correcting illness and selecting desirable traits becomes easier to approach? Those questions don't have molecular answers.

The People Around the Science

This is the part of CRISPR that interests me most.

The technology tends to attract two competing stories. In one, gene editing liberates us from diseases that have caused enormous suffering. In the other, we are approximately three laboratory mishaps away from ordering designer babies from an app. Reality is less cooperative.

A technology can be genuinely life-changing and still create new inequalities. A treatment can be developed with good intentions and become available first to people with money, geography, insurance, or political access on their side. Regulators can act responsibly and still be working with incomplete information. Scientists can understand the biology better than anyone alive and still disagree about acceptable risk.

None of that makes CRISPR sinister. It makes CRISPR human.

And humans have a long history of taking astonishing inventions and immediately adding power, money, ambition, fear, and politics to the equation. That's where things get interesting.

Why CRISPR Found Its Way Into My Fiction

CRISPR sits underneath much of The Helix Chronicles, but I've never been particularly interested in using gene editing as a futuristic prop. What fascinated me was what people might do once the technology became powerful enough to tempt them.

What happens when someone has the ability to prevent suffering and becomes convinced that gives them the right to decide what should be changed? What happens when a public-health argument starts quietly absorbing ideas about behavior, desirability, or social good? What happens when access to a breakthrough depends on an institution whose motives are considerably less advanced than its science?

Those questions eventually became more interesting to me than the mechanics of gene editing itself.

Memphis gave me the perfect place to explore them because I wanted the consequences to land somewhere recognizable. Families, courtrooms, hospitals, neighborhoods, politics. People who aren't debating biotechnology at a conference but suddenly have to live with decisions made by those who are.

That's also why the technology in my books is rarely the thing I distrust most. The people making decisions around it usually earn that distinction.

The Part We Don't Get to Outsource

I don't think CRISPR requires us to choose between excitement and fear. I'm enormously excited by what gene editing may make possible. A technology capable of relieving suffering on this scale deserves that excitement. It also deserves scrutiny proportional to its power.

Science can tell us whether an edit works, what risks researchers can measure, and what becomes technically possible next. It cannot decide how access should be distributed, which uses society should permit, whose definition of improvement counts, or how much authority we're willing to give institutions making those decisions.

We have to do that part ourselves. And we're going to be doing it while the science keeps moving.

That's the tension I keep coming back to, both here and in my fiction. CRISPR can give us remarkable new choices. It cannot make us wise enough to choose well.

Unfortunately, that technology is still in development.